A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID‐19

Zheng, Zhong; Dong, Minglin; Hu, Ke

doi:10.1002/jmv.26040

Cited by 48 publications

(50 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our observations come in line with reports on clinical cases observed in China, Italy, and Spain [11][12][13][14][15]. All cases were treated by ozone autohemotherapy, and none of cases were treated by rectal ozone therapy.…”

Section: Discussionsupporting

confidence: 91%

“…To date, we are not aware of the existence of any study that has treated patients with COVID-19 with rectal ozone. The number of sessions in autohemotherapy (5-7 sessions) [11][12][13][14][15] was similar to rectal ozone sessions applied in this study (6.75 sessions on average).…”

Section: Discussionmentioning

confidence: 72%

“…These two cases were matched and compared with two other subjects that were not treated by ozone. Since all four patients followed the Chinese Guidelines for COVID-19 management, it is expected that ozone therapy is responsible for the good effects observed in the ozone autohemotherapy cases [14].…”

Section: Discussionmentioning

confidence: 99%

“…As a summary, the experience in patients with COVID-19 treated in Italy, China, and Spain refers to ozone applied under the autohemotherapy technique [11][12][13][14][15]. To date, we are not aware of the existence of any study that has treated patients with COVID-19 with rectal ozone.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results

Fernández-Cuadros

Albaladejo-Florín

Álava-Rabasa

et al. 2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

The aim of this study is to evaluate the effectiveness of rectal ozone (O 3) in COVID-19 patients with severe pneumonia admitted at Hospital Universitario Santa Cristina, Madrid. In a before-and-after study, four patients admitted with severe bilateral pneumonia due to COVID-19 were treated with rectal ozone and confirmed with (+) RT-PCR for SARS-CoV-2 and evaluated afterwards. The analyzed outcome variables were as follows: (a) clinical improvement (O 2 saturation and O 2 supply); (b) biochemical improvement (fibrinogen, D-dimer, urea, ferritin, LDH, IL-6, and CRP); (c) radiological improvement. The treatment protocol consisted of 5 sessions (1 session/day) of intra-rectal ozone, applied in a volume of 100 mL and a concentration of 35 μg/mL. The Protocol was previously approved by the Hospital's Health Care Ethics Committee (CEAS) (Report 15/4/2020) for compassionate use in the face of this exceptional pandemic situation, and prior informed consent was obtained from the patient/legal representative. The patients improved oxygen saturation, as observed by the lower number of desaturations and the lower supply of O 2. Biomarkers of inflammation decreased (fibrinogen, D-dimer, urea, ferritin, LDH, IL-6, and CRP). Finally, the radiological signs of bilateral viral pneumonitis improved between 1 and 2 grades based on Taylor's radiological scale. Rectal ozone decreases O 2 supply and improves O 2 saturation, decreases inflammation biomarkers, and improves Taylor's radiological grade in patients with severe COVID-19 pneumonia. Rectal ozone is a safe, effective, cheap, and simple alternative capable of acting on the SARS-CoV-2 virus, and it is presented as an adjunctive therapeutic option to consider in the management of severe bilateral COVID-19 pneumonia.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results

Fernández-Cuadros

Albaladejo-Florín

Álava-Rabasa

et al. 2020

SN Compr. Clin. Med.

View full text Add to dashboard Cite

show abstract

“…21 Others have reported the use of ozonated autohemotherapy in patients with severe COVID-19 pneumonia, however, they had limitations. 22,23 The Scientific Society of Oxygen-Ozone Therapy (SIOOT) described a case series of 73 patients, of whom 32.8% were intubated and 67.1% were non-intubated. 24 Of all the intubated-patients, 62.5% were extubated after five sessions with ozone autohemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Ozone therapy for patients with COVID-19 pneumonia: a Quasi-Randomized Controlled Trial

Hernández¹,

Viñals²,

Pablos³

et al. 2020

Preprint

View full text Add to dashboard Cite

Importance Aside from supportive management, there remains no specific treatment for Coronavirus Disease 2019 (COVID-19). Objective: Determine whether ozonated autohemotherapy is associated with a shorter time to clinical improvement in patients with severe COVID-19 pneumonia. Design: Single-center proof-of-concept prospective cohort study. Setting: Internal Medicine ward at Policlinica Ibiza Hospital, Spain. Participants: Eighteen consecutive patients with laboratory confirmed COVID-19 infection and severe pneumonia who were admitted to hospital between 20th March and 19th April 2020. Exposures: Patients in the ozonated autohemotherapy arm received hemotherapy twice daily starting on the day of admission for a median of 4 days. Each treatment involved administration of 200 mL autologous whole blood enriched with 200 mL of oxygen-ozone mixture with a 40 μg/mL ozone concentration. Patients in the control arm received supportive care. Assignment to hemotherapy versus usual care was determined based on the admitting physician on the day of admission, with only one of the three possible physicians prescribing ozonated autohemotherapy Main Outcomes: The primary outcome was time from hospital admission to clinical improvement, which was defined as either hospital discharge or a two-point improvement in clinical status measured on a six-point ordinal scale. Secondary outcomes were clinical improvement measured on the 7th, 14th and 28th day after admission, as well as time to a 2-fold reduction in concentrations of C-protein reactive, ferritin, D-dimer and lactate dehydrogenase. Results: The mean age of the cohort was 68 y and 72% (n=13) were male. Nine patients (50%) received ozonated autohemotherapy beginning on the day of admission. In unadjusted comparisons, ozonated autohemotherapy was associated with significantly shorter time to clinical improvement (median [IQR]), 7 days [6-10] vs 28 days [8-31], p=0.04) and significantly higher proportion of patients achieving 14-day clinical improvement (88.8% vs 33.3%, p=0.01). In risk-adjusted analyses, ozonated autohemotherapy was associated with a shorter mean time to clinical improvement (-11.3 days, p=0.04, 95% CI -22.25 to -0.42). Conclusions and Relevance: Ozonated autohemotherapy was associated with a significantly shorter time to clinical improvement in this prospective cohort study. Given the small sample size and single-center study design, these observations require evaluation in larger randomized controlled trials.

show abstract

Ozone as adjuvant support in the treatment of COVID‐19: A preliminary report of probiozovid trial

Araimo

Imperiale

Tordiglione

et al. 2020

Journal of Medical Virology

104

View full text Add to dashboard Cite

The evaluation of new therapeutic resources against coronavirus disease 2019 (COVID‐19) represents a priority in clinical research considering the minimal options currently available. To evaluate the adjuvant use of systemic oxygen‐ozone administration in the early control of disease progression in patients with COVID‐19 pneumonia. PROBIOZOVID is an ongoing, interventional, randomized, prospective, and double‐arm trial enrolling patient with COVID‐19 pneumonia. From a total of 85 patients screened, 28 were recruited. Patients were randomly divided into ozone‐autohemotherapy group (14) and control group (14). The procedure consisted in a daily double‐treatment with systemic Oxygen–ozone administration for 7 days. All patients were treated with ad interim best available therapy. The primary outcome was delta in the number of patients requiring orotracheal‐intubation despite treatment. Secondary outcome was the difference of mortality between the two groups. Moreover, hematological parameters were compared before and after treatment. No differences in the characteristics between groups were observed at baseline. As a preliminary report we have observed that one patient for each group needed intubation and was transferred to ITU. No deaths were observed at 7–14 days of follow up. Thirty‐day mortality was 8.3% for ozone group and 10% for controls. Ozone therapy did not significantly influence inflammation markers, hematology profile, and lymphocyte subpopulations of patients treated. Ozone therapy had an impact on the need for the ventilatory support, although did not reach statistical significance. Finally, no adverse events related to the use of ozone‐autohemotherapy were reported. Preliminary results, although not showing statistically significant benefits of ozone on COVID‐19, did not report any toxicity.

show abstract

A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID‐19

Cited by 48 publications

References 6 publications

Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results

Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results

Ozone therapy for patients with COVID-19 pneumonia: a Quasi-Randomized Controlled Trial

Ozone as adjuvant support in the treatment of COVID‐19: A preliminary report of probiozovid trial

Contact Info

Product

Resources

About